TRPM4 and myeloid sarcoma: Given its predominant expression in reactive astrocytes, and the important pro-inflammatory role of astrocytes in MS and EAE, the SUR1-TRPM4 channel may represent a novel therapeutic approach for disease modification to reduce peripheral immune cell entry into the CNS without compromising the function of peripheral immune cells.